ArticleClinical transplantation2026
Risk Factors for Pneumocystis Jirovecii Pneumonia Among Kidney Transplant Recipients in Southeast France: A 10 Years Case-Control Study.
Article in Clinical transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPneumocystis jirovecii is an opportunistic fungus responsible for Pneumocystis pneumonia (PJP) in hosts with impaired cell-mediated immunity, particularly solid organ transplant recipients. The aim of our study was to identify risk factors associated with PJP in kidney transplant recipients (KTRs).
methodsWe conducted a single-center, retrospective, case-control study (1 case per 2 controls) of KTRs from May 2014 to May 2024. Cases were defined as KTRs with a confirmed diagnosis of PJP, while controls were matched on transplant and hospitalization dates (±3 months) and had not developed PJP during the follow-up period. Statistical analysis was performed using conditional logistic regression models to examine potential risk factors for PJP, with a forward stepwise selection procedure to identify significant variables.
resultsA total of 37 KTRs with PJP and 74 matched controls were included. The median time from transplantation to diagnosis was 60 months. Two cases occurred before prophylaxis was discontinued, followed by 11 cases within the next six months. Baseline characteristics were similar between cases and controls. The number of day hospital or outpatient visits in the year prior to inclusion was significantly higher in cases than in controls (mean 11.11 vs. 8.89 visits, p = 0.04). Severe lymphopenia (<0.5 G/L) was the most significant risk factor for the development of PJP.
conclusionsThe most significant risk factor observed was severe lymphopenia. These findings underscore the importance of strengthening infection prevention measures, including strict adherence to standard precautions, appropriate isolation protocols, and targeted prophylaxis for high-risk individuals during periods of increased transmission. Further studies are needed to optimize PJP prophylaxis for KTRs with severe lymphopenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.